Meera Mohan
@MeeraMohanMD
Followers
1K
Following
5K
Media
28
Statuses
1K
Assistant Professor of Medicine, Myeloma Clinical Faculty @MCW Proud UAMS Alumnus @UAMS myeloma.@AACR/ ASCO Vail 2022 Alumni. #myeloma #MRD#Clinical trial
Milwaukee, WI
Joined January 2019
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma | Blood Advances | American Society of Hematology .@UAMSMyeloma.
ashpublications.org
Key Points. MRD conversion occurs in 39% of MRD− MM patients and reliably predicts future relapse.MRD conversion within 10 years of diagnosis confers an in
6
20
91
RT @HadidiSamer: Check our recent work: Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort #mmsm @MeeraMo….
0
12
0
RT @MansiShahMD: Our multicenter series shows bispecific antibodies may offer meaningful CNS activity with manageable safety. Led by fellow….
onlinelibrary.wiley.com
Click on the article title to read more.
0
13
0
RT @ovanoekelen: Excited as co-first author to share our NEJM case report: we describe the successful personalized treatment of a CAR⁺ T-ce….
0
7
0
RT @RahulBanerjeeMD: Excellent & important #MMsm work by @nishi_shah_ @JanakiramMurali et al!. Validating @iStopMM 🇮🇸 SMM prediction in the….
0
5
0
RT @RahulBanerjeeMD: @MTomasson @HiraSMian @bdermanmd @themednet @ZanwarSaurabh @EagleMyeloma @HagenPatrick81 I learned a new phrase today….
0
5
0
RT @OSUHematology: Next month is our Annual OSU Hematology Symposium. 🗓️Fri. Sept 26! . 🎉 Don’t miss this opportunity to engage with lea….
0
7
0
RT @JHillengass: Fantastic team work with colleagues from Dana Farber and Hemn Mohammadpour's lab led to our discovery of immunosuppressive….
pubmed.ncbi.nlm.nih.gov
Understanding the roles of myeloid cells in the tumor microenvironment (TME) has emerged as a promising strategy to identify novel targets to counteract the immunosuppressive barriers protecting...
0
4
0
RT @RahulBanerjeeMD: Fascinating @BloodAdvances #MMsm work by MDACC & Moffitt: Can 💩 microbiome predict responses & AEs after ide-cel CAR-T….
0
4
0
RT @DrJulieVose: @ASCO/@AACR Clinical Trials Workshop is always a great week of learning for everyone!.
0
2
0
RT @Transplant_Doc: Outcomes of patients with NDMM with del (1p) following autoHCT. Median PFS 30.2 months, median OS NR; concomitant del(1….
0
3
0
RT @vsanchorawala: Kidney transplantation in PCDs is now a real option for select patients with ESKD due to MM, AL amyloidosis, or MGRS. A….
kidney-international.org
Patients with plasma cell dyscrasias, including multiple myeloma, AL amyloidosis, and monoclonal gammopathy of renal significance, face a high burden of end-stage kidney disease, which limits...
0
23
0
RT @MalinHultcrantz: Management recommendations for kidney transplantation in patients with plasma cell dyscrasia - Kidney International ht….
kidney-international.org
Patients with plasma cell dyscrasias, including multiple myeloma, AL amyloidosis, and monoclonal gammopathy of renal significance, face a high burden of end-stage kidney disease, which limits...
0
10
0
RT @RahulBanerjeeMD: Come work with us!!. cc @MadhavDhodapkar @AJPortuguese @DimaDanai @RichaThakurMD and many more not on Twitter!.
0
11
0
RT @Transplant_Doc: Rewriting Risk: A Data-Driven Look at Myeloma Genetics | Journal of Clinical Oncology #mmsm #bmtsm @JCO_ASCO @DrKrinaP….
ascopubs.org
0
12
0
RT @RahulBanerjeeMD: @oncodaily @Myeloma_Doc @MeeraMohanMD @KRejeski @GKaurMD @DrNikitaMehra @NoopurRajeMD Thank you for featuring this!. T….
0
1
0
RT @oncodaily: Myeloma Paper of the Day, July 22nd, Suggested by Robert Orlowski (@Myeloma_Doc). @RahulBanerjeeMD @MeeraMohanMD @KRejeski @….
0
4
0
RT @Myeloma_Doc: #Myeloma Paper of the Day: Viewpoint piece makes evidence-based arguments for use of primary prophylaxis as a safer and si….
0
11
0
RT @HadidiSamer: Check our recent work @UAMSMyeloma published @BloodAdvances : . Prognostic Impact of Focal Lesion Location and Persistence….
0
12
0
RT @RahulBanerjeeMD: Excellently written @NatureMedicine review, and honestly the best graphics re: CAR-T toxicities (inc. infections & SPM….
0
42
0